Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...

Galapagos plans to split into two entities by mid-2025, focusing its core business on cell therapies while spinning off a new ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...